Zacks11d agobullish
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo LaunchCytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.
Notícias
Apenas manchetes de alto sinal — eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
48last 24h
1672last 7d
313🟢 bullish (7d)
171🔴 bearish (7d)
136publishers
24/7 Wall St.11d agobearish
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market CrashDividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
